• ImmunityBio faces a securities class action tied to investor purchases from Jan. 19, 2026 to Mar. 24, 2026.
• The case follows an FDA warning letter flagging what it called false or misleading promotional claims that Anktiva could cure, prevent, or treat cancers beyond its approved bladder cancer use.
• Shares fell more than 21% on Mar. 24, 2026, wiping out nearly USD 2 billion in market value.
• The lead plaintiff deadline is May 26, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605210900PR_NEWS_USPR_____SF64991) on May 21, 2026, and is solely responsible for the information contained therein.